Neutral Glenmark Pharma; target of Rs 600: Motilal Oswal
Motilal Oswal recommended Neutral rating on Glenmark Pharma with a target price of Rs 600 in its research report dated August 16, 2021.19-08-2021
19-08-2021
Earnings Call for Q1FY22 of Glenmark Pharmaceuticals
Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.16-08-2021
Q1FY22 Result Announced for Glenmark Pharmaceuticals Ltd.
Highlights for Q1 FY 2021-22: Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY for Q1 FY 2021-22. India Business grew by 57 % YoY to Rs. 12,250 Mn. North America Business recorded growth of 6% YoY to Rs. 7,878 Mn. Europe Business grew by 12% YoY to Rs. 3,059 Mn. ROW Business grew by 27% YoY to Rs. 2,686 Mn. API Business grew by 29% YoY to Rs. 3040 Mn. EBITDA of Rs. 5,736 Mn grew by 20% YoY with margins of 19%. For the First Quarter of FY 2021-22, Glenmark’s consolidated revenue was at Rs. 29,649 Mn. as against Rs. 23,448 Mn recording an increase of 26% Consolidated EBITDA grew by 20% to Rs. 5,736 Mn in the quarter ended June 30, 2021 as against Rs. 4781 Mn. in the previous corresponding quarter. Profit After Tax (PAT) was at Rs. 3,065 Mn for the quarter ended June 30, 2021 as compared to Rs. 2540 Mn in the previous corresponding quarter, registering an increase of 21% YoY. “It was a landmark quarter for the company with positive momentum in all our key markets. Our commitment towards the fight against COVID19 was reflected in FabiFlu® becoming the number one brand in the India pharma market in April. We launched our first nebulizer, Arformoterol Inhalation solution from Monroe, US.” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals. He further added, “We have a strategic roadmap to grow consistently and profitably over the year. “We have a clear plan in place to reduce debt by enhancing free cash, prioritizing over R&D; investments and capital expenditure going forward.” Result PDF16-08-2021
Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY
Glenmark Pharmaceuticals Limited today announced its financial results for the first quarter ended June 30, 202114-08-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Unaudited Financial Results (Standalone And Consolidated) For The First Quarter Ended June 30, 2021
Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the First Quarter ended June 30, 2021. The said meeting of the Board commenced at 5.30 p.m. and concluded at 9.15 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release Investor Presentation and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com13-08-2021
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Monday, August 16, 2021 at 9:30 a.m. - 10:30 a.m. (1ST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.06-08-2021
Glenmark Pharmaceuticals Ltd - 532296 - Update On Listing Of Equity Shares Of Glenmark Life Sciences Limited
This is further to our intimations dated April 16, 2021, July 20, 2021 and August 3, 2021, on the subject mentioned above, we would like to inform you that the equity shares of the wholly owned subsidiary of the Company, Glenmark Life Sciences Limited, were admitted for listing by BSE Limited and National Stock Exchange of India Limited with effect from August 6, 2021.06-08-2021
Glenmark Pharmaceuticals Ltd - 532296 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, August 13, 2021, inter alia, to consider and approve the Unaudited Financial Results of the Company for the first quarter ended June 30, 2021. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2021 to August 15, 2021 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First quarter ended June 30, 2021.05-08-2021
Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The First Quarter Ended June 30, 2021
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2021 ,inter alia, to consider and approve Unaudited Financial Results Of The Company For The First Quarter Ended June 30, 202105-08-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Initial Public Offering ('Offer') Of Equity Shares Of Our Wholly Owned Subsidiary 'Glenmark Life Sciences Limited'
This is further to our intimations dated April 16, 2021 and July 20, 2021 regarding the submission of the draft red herring prospectus dated April 16, 2021 ('DRHP'), with the Securities and Exchange Board of India and filing of the red herring prospectus dated July 19, 2021 with the Registrar of Companies, Pune at Maharashtra ('ROC') by our wholly owned subsidiary, Glenmark Life Sciences Limited. We would like to inform you of the following: a. The IPO comprised of a fresh issue of 14,722,222 equity shares by Glenmark Life Sciences Limited and an offer for sale of 6,300,000 equity shares by the Company. The IPO opened for subscription on July 27, 2021 and closed on July 29, 2021. b. Glenmark Life Sciences Limited filed the prospectus with the ROC on July 30, 2021. c. The equity shares of the Glenmark Life Sciences Limited, pursuant to the IPO, were allotted at an offer price of Rs. 720 per equity share, to the successful bidders on August 3, 2021.03-08-2021